{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:49:57Z","timestamp":1793749797721,"version":"4.6.1"},"reference-count":69,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with cancer face an increased risk of venous thromboembolism (VTE), and breakthrough thrombosis despite anticoagulation, with a 6-month cumulative incidence of 5% to 8%. The management of these events is challenging. Confirming suspected breakthrough thrombosis requires imaging review, ideally by comparison with postindex baseline studies, because residual thrombus is common and may mimic recurrence. When breakthrough thrombosis is confirmed, several potential contributing factors should be assessed. Nonadherence is common among patients undergoing anticoagulation and should be evaluated through detailed medication history. Measurement of drug-specific plasma levels, when available, may assist in confirming nonadherence. In patients on low-molecular-weight heparin (LMWH), underlying prothrombotic conditions such as heparin-induced thrombocytopenia or acquired antithrombin deficiency must also be considered. For patients receiving oral anticoagulants, drug-drug interactions and impaired gastrointestinal absorption should be excluded. Therapeutic strategies are guided by limited evidence, primarily from observational studies. Current practice generally favors switching to therapeutic LMWH if the patient was on oral anticoagulation, escalating LMWH dosing by 25% to 33% if already on therapeutic LMWH, or increasing LMWH to weight-adjusted therapeutic dose if treatment was subtherapeutic. Despite treatment adjustments, recurrence and bleeding risks remain substantial. In this review, we outline common clinical scenarios of breakthrough thrombosis in patients with cancer and critically appraise the available evidence to inform treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030790","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T20:57:53Z","timestamp":1768942673000},"page":"1804-1813","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["How I treat breakthrough thrombosis in patients with cancer"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5077-6485","authenticated-orcid":false,"given":"Caterina E.","family":"Marx","sequence":"first","affiliation":[{"name":"1Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada"},{"name":"2Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"1Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2026041611213520600_bib1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2026041611213520600_bib2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026041611213520600_bib3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"2026041611213520600_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026041611213520600_bib5","doi-asserted-by":"crossref","first-page":"ehaf453","DOI":"10.1093\/eurheartj\/ehaf453","article-title":"Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis","author":"Khan","year":"2025","journal-title":"Eur Heart J"},{"issue":"14","key":"2026041611213520600_bib6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2026041611213520600_bib7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1538-7836.2009.03324.x","article-title":"Validation of a diagnostic approach to exclude recurrent venous thromboembolism","volume":"7","author":"Le Gal","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026041611213520600_bib8","first-page":"402","article-title":"The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis","volume":"88","author":"Prandoni","year":"2002","journal-title":"Thromb Haemost"},{"issue":"4","key":"2026041611213520600_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1160\/TH05-12-0791","article-title":"Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism","volume":"95","author":"Righini","year":"2006","journal-title":"Thromb Haemost"},{"issue":"6","key":"2026041611213520600_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1538-7836.2005.01323.x","article-title":"D-Dimer test in cancer patients with suspected acute pulmonary embolism","volume":"3","author":"Di Nisio","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026041611213520600_bib11","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1016\/j.jtha.2025.06.019","article-title":"Performance of clinical decision rules in patients presenting with suspected recurrent venous thromboembolism: a multicenter prospective cohort study","volume":"23","author":"Mai","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026041611213520600_bib12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jth.12301","article-title":"The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH","volume":"11","author":"Ageno","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"22","key":"2026041611213520600_bib13","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism","volume":"2","author":"Lim","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026041611213520600_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1160\/TH13-04-0336","article-title":"Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis","volume":"111","author":"Donadini","year":"2014","journal-title":"Thromb Haemost"},{"issue":"5","key":"2026041611213520600_bib15","first-page":"515","article-title":"Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis","volume":"87","author":"Piovella","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"2026041611213520600_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1378\/chest.129.1.192","article-title":"Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review","volume":"129","author":"Nijkeuter","year":"2006","journal-title":"Chest"},{"issue":"6","key":"2026041611213520600_bib17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jtha.2023.01.030","article-title":"Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data","volume":"21","author":"Robin","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026041611213520600_bib18","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.7326\/0003-4819-129-12-199812150-00009","article-title":"The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism","volume":"129","author":"Kearon","year":"1998","journal-title":"Ann Intern Med"},{"issue":"14","key":"2026041611213520600_bib19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.117.030687","article-title":"Ultrasound for lower extremity deep venous thrombosis: multidisciplinary recommendations from the Society of Radiologists in Ultrasound Consensus Conference","volume":"137","author":"Needleman","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"2026041611213520600_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.thromres.2005.02.011","article-title":"Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis","volume":"117","author":"Linkins","year":"2006","journal-title":"Thromb Res"},{"issue":"9","key":"2026041611213520600_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"2026041611213520600_bib22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"2026041611213520600_bib23","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"2026041611213520600_bib24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041611213520600_bib25","doi-asserted-by":"crossref","first-page":"230130","DOI":"10.1183\/20734735.0130-2023","article-title":"Multimodality imaging of acute and chronic pulmonary thromboembolic disease","volume":"20","author":"Muscogiuri","year":"2024","journal-title":"Breathe"},{"issue":"6 suppl 2","key":"2026041611213520600_bib26","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.2214\/AJR.04.1955","article-title":"Acute and chronic pulmonary emboli: angiography\u2013CT correlation","volume":"186","author":"Wittram","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"2026041611213520600_bib27","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/j.1538-7836.2011.04533.x","article-title":"Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence","volume":"9","author":"Hamadah","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026041611213520600_bib28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jvir.2023.06.013","article-title":"Society of Interventional Radiology position statement on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents","volume":"34","author":"Vedantham","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"2026041611213520600_bib29","doi-asserted-by":"crossref","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"Salmasi","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"2026041611213520600_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.thromres.2015.07.007","article-title":"Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale","volume":"136","author":"Castellucci","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"2026041611213520600_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026041611213520600_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026041611213520600_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/hematology.2024000666","article-title":"DOACs: role of anti-Xa and drug level monitoring","volume":"2024","author":"Mithoowani","year":"2024","journal-title":"Hematology"},{"issue":"11","key":"2026041611213520600_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non\u2013vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026041611213520600_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-0716-3175-1_22","article-title":"An overview of heparin monitoring with the anti-Xa assay","volume":"2663","author":"Dean","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2026041611213520600_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"issue":"2","key":"2026041611213520600_bib69","doi-asserted-by":"crossref","first-page":"e24S-e43S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"2026041611213520600_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2019.01.007","article-title":"Monitoring of heparins in antithrombin-deficient patients","volume":"175","author":"Croles","year":"2019","journal-title":"Thromb Res"},{"key":"2026041611213520600_bib37","first-page":"101056","article-title":"French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update","volume":"84","author":"Mah\u00e9","year":"2023","journal-title":"Respir Med Res"},{"issue":"2","key":"2026041611213520600_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2026041611213520600_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejim.2022.02.020","article-title":"Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence","volume":"100","author":"Jim\u00e9nez-Fonseca","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2026041611213520600_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2026041611213520600_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update","volume":"38","author":"Key","year":"2020","journal-title":"JCO"},{"issue":"4","key":"2026041611213520600_bib43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2026041611213520600_bib44","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026041611213520600_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/asheducation-2010.1.144","article-title":"Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants","volume":"2010","author":"Lee","year":"2010","journal-title":"Hematology"},{"issue":"suppl 1","key":"2026041611213520600_bib46","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1016\/S0049-3848(12)70035-X","article-title":"Treatment of established thrombotic events in patients with cancer","volume":"129","author":"Lee","year":"2012","journal-title":"Thromb Res"},{"issue":"5","key":"2026041611213520600_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026041611213520600_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2026041611213520600_bib49","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026041611213520600_bib50","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.jtha.2025.02.022","article-title":"Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study","volume":"23","author":"Lanting","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026041611213520600_bib51","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.jtha.2025.08.022","article-title":"Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study","volume":"23","author":"Lanting","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026041611213520600_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9343(01)00840-3","article-title":"Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy","volume":"111","author":"Luk","year":"2001","journal-title":"Am J Med"},{"issue":"3","key":"2026041611213520600_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2141.2007.06679.x","article-title":"Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism","volume":"138","author":"Lobo","year":"2007","journal-title":"Br J Haematol"},{"key":"2026041611213520600_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2020.01.010","article-title":"Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients","volume":"187","author":"Van Es","year":"2020","journal-title":"Thromb Res"},{"issue":"3","key":"2026041611213520600_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11239-020-02042-6","article-title":"Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes","volume":"49","author":"McIlroy","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2026041611213520600_bib67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11239-021-02377-8","article-title":"Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study","volume":"52","author":"Lai","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2026041611213520600_bib68","doi-asserted-by":"crossref","first-page":"22437","DOI":"10.1038\/s41598-022-26947-9","article-title":"Clinical characteristics, management strategies and outcomes of patients with recurrent venous thromboembolism in the real world","volume":"12","author":"Yamashita","year":"2022","journal-title":"Sci Rep"},{"key":"2026041611213520600_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2022.12.008","article-title":"Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban","volume":"222","author":"Maximiliano","year":"2023","journal-title":"Thromb Res"},{"issue":"5","key":"2026041611213520600_bib64","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11239-024-02978-z","article-title":"Equivalent thrombotic risk with warfarin, dabigatran, or enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy","volume":"57","author":"Shyu","year":"2024","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"2026041611213520600_bib55","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/17512433.2025.2585448","article-title":"Drug-drug interactions in anticoagulant therapy: a focus on oncology patients","volume":"18","author":"Vrotniakaite-Bajerciene","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"21","key":"2026041611213520600_bib56","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"key":"2026041611213520600_bib57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb Res"},{"issue":"3","key":"2026041611213520600_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2026041611213520600_bib59","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jtha.2025.03.026","article-title":"Direct oral anticoagulant failure in patients with venous thromboembolism\u2014why and what next?","volume":"23","author":"Swan","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026041611213520600_bib60","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/FJC.0000000000001142","article-title":"Direct acting oral anticoagulants following gastrointestinal tract surgery","volume":"78","author":"Hakeam","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026041611213520600_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.thromres.2024.01.007","article-title":"Pharmacokinetics of direct oral anticoagulants after bariatric surgery: a retrospective cohort study","volume":"235","author":"Gunka","year":"2024","journal-title":"Thromb Res"},{"issue":"5","key":"2026041611213520600_bib62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2026041611213520600_bib63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/8755122516646384","article-title":"Administration of direct oral anticoagulants through enteral feeding tubes","volume":"32","author":"Peterson","year":"2016","journal-title":"J Pharm Technology"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/16\/1804\/2513177\/blood_bld-2025-030790-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/16\/1804\/2513177\/blood_bld-2025-030790-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:21:51Z","timestamp":1776352911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/16\/1804\/566135\/How-I-treat-breakthrough-thrombosis-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":69,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030790","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,16]]},"published":{"date-parts":[[2026,4,16]]}}}